Variation in Treatment Associated With Life Expectancy in a Population-Based Cohort of Men With Early-Stage Prostate Cancer
Variation in Treatment Associated With Life Expectancy in a Population-Based Cohort of Men With Early-Stage Prostate Cancer
复制标题
DOI：
10.1002/cncr.28926
复制
发表时间：
2014-12-01
期刊：
影响因子：
6.2
通讯作者：
Saigal, Christopher
中科院分区：
文献类型：
--
作者：
Daskivich, Timothy J.;Lai, Julie;Saigal, Christopher
由于预期寿命的不确定性，患有主要合并症的男性有过度治疗前列腺癌的风险。我们试图描述不同年龄和合并症负担在diagnosis.METHODSWe抽样96，032名男性年龄66岁的早期前列腺癌谁有格里森评分7和诊断在1991年至2007年期间，从监测，流行病学和最终结果-医疗保险数据库的预期寿命和治疗。我们计算了其他原因死亡的累积发生率，并确定了按年龄和Charlson合并症指数评分定义的亚组的治疗模式。预期寿命因年龄和合并症评分而异，
BACKGROUNDMen with major comorbidities are at risk for overtreatment of prostate cancer due to uncertainty regarding their life expectancy. We sought to characterize life expectancy and treatment in a population-based cohort of men with differing ages and comorbidity burdens at diagnosis.METHODSWe sampled 96,032 men aged 66 years with early-stage prostate cancer who had Gleason scores 7 and were diagnosed during 1991 to 2007 from the Surveillance, Epidemiology, and End Results-Medicare database. We calculated cumulative incidence of other-cause mortality and determined treatment patterns among subgroups defined by age and Charlson comorbidity index scores.RESULTSOverall, life expectancy was 50%) for 50,049 of 96,032 men (52%). Life expectancy differed by age and comorbidity score and was